Cargando…
Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis
SIMPLE SUMMARY: Breast cancer subtypes are characterized by the expression and activity of estrogen-, progesterone- and HER2-receptors and differ by the treatment as well as patient prognosis. Tumors of the HER2-subtype overexpress this receptor and are successfully targeted with anti-HER2 therapies...
Autores principales: | Kemmer, Svenja, Berdiel-Acer, Mireia, Reinz, Eileen, Sonntag, Johanna, Tarade, Nooraldeen, Bernhardt, Stephan, Fehling-Kaschek, Mirjam, Hasmann, Max, Korf, Ulrike, Wiemann, Stefan, Timmer, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139462/ https://www.ncbi.nlm.nih.gov/pubmed/35625984 http://dx.doi.org/10.3390/cancers14102379 |
Ejemplares similares
-
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs
por: Henjes, F, et al.
Publicado: (2012) -
IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment
por: Maia, Ana, et al.
Publicado: (2021) -
Metabolic transformations in breast cancer subtypes
por: Mitra, Devina, et al.
Publicado: (2014) -
Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts
por: Berdiel-Acer, Mireia, et al.
Publicado: (2021) -
BlotIt—Optimal alignment of Western blot and qPCR experiments
por: Kemmer, Svenja, et al.
Publicado: (2022)